Results 131 to 140 of about 8,893 (235)

Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1499-1507, February 2026.
Abstract Aims Published literature has raised concerns regarding a causal association between glucagon‐like peptide 1 receptor agonist (GLP‐1RA) use and thyroid cancer risk in adults. In this analysis, we evaluated the association between thyroid cancer risk and GLP‐1RA use.
Tina Vilsbøll, Michael Stellfeld, Vanita R. Aroda, Sune Dandanell, Jens‐Peter David, Ceyda T. P. Kristiansen, Søren Rasmussen, Fiona L. Roberts, Laszlo Hegedüs   +8 more
wiley   +1 more source

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1136-1149, February 2026.
Abstract Aim Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been established as effective treatments for type 2 diabetes, offering benefits beyond glycaemic control; however, their associations across multiple health outcomes remain insufficiently assessed.
Dongjin Yeo, Yeona Jo, Jinyoung Jeong, Yi Deun Jeong, Ho Geol Woo, Yejun Son, Sunyoung Kim, Sang Youl Rhee, Dong Keon Yon   +8 more
wiley   +1 more source

Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study

Frontiers in Endocrinology
IntroductionGlobal phase III clinical trials have shown superior hypoglycemic efficacy to insulin and other oral hypoglycemic agents. However, there is a scarcity of real-world data comparing different glucagon-like peptide 1 receptor agonist (GLP-1RA ...
Yan Jiang, Han-Sheng Bai, Guo-Xin Liu, Shi-Yi Wang, Li Yin, Zhao-Ting Hou, Chen-Yang Zhao, Guang-Jun Fan   +7 more
doaj   +1 more source

PIONEER REAL Saudi Arabia: A multicentre, prospective, real‐world study of once‐daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1304-1314, February 2026.
Abstract Aim PIONEER REAL Saudi Arabia investigated real‐world clinical outcomes associated with the use of once‐daily oral semaglutide in adults with type 2 diabetes (T2D). Materials and Methods This was a 34‐ to 44‐week multicentre, prospective, open‐label study in adults with T2D, who were treatment‐naive to injectable glucose‐lowering medication ...
Hussein ElBadawi, Nader Albalkhi, Ibrahim Al Kadhim, Ahmed Elsadig, Dimitrios Baltzis, Mohamed Hassan Hatahet, Mahmoud Ismail, Said Khader, Christina Louise Rasmussen, Stine Hedegaard Scheuer, Ahmed Shalaby, Mohammed Almehthel   +11 more
wiley   +1 more source

GLP‐1 receptor agonists for treating obesity without diabetes: A systematic review and meta‐analysis of economic evaluations

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1339-1349, February 2026.
Abstract Aim To pool the incremental net benefits (INBs) of using glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) for treating obesity without diabetes. Materials and Methods PubMed, Embase, EconLit, CEA Registry, ProQuest Dissertation and Theses Global were searched from inception to April 2024.
Teerapon Dhippayom, Manuel Meraz, Haeseon Lee, Chin Hur, John M. Inadomi, Sajesh K. Veettil, Jeffrey D. Dunn, Nathorn Chaiyakunapruk   +7 more
wiley   +1 more source

Knowledge, Attitude and Practice about Glucagon-like Peptide-1 Receptor Agonist Among the Physicians of Prince Mohammed bin Abdulaziz Hospital & Primary Health Care, National Guard, Saudi Arabia

Journal of Pharmaceutical Research
Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a newly approved medication in the management of Diabetes Mellitus. GLP-1RA has potential adverse effects and risks such as gastrointestinal symptoms, pancreatitis, and thyroid cell neoplasia ...
Meshari A Turjoman, Amani Mahrous, Ahmed A Ozbuk, Raghad M Alhujaili, Hessan T Bagasi, Khulood A Alsiary   +5 more
doaj   +1 more source

Heart matters: How glucose‐ and lipid‐modulating drugs remodel epicardial adipose tissue accumulation, inflammatory patterns and browning

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 878-894, February 2026.
Abstract Epicardial adipose tissue (EAT) is a metabolically active visceral fat depot located between the myocardium and the visceral pericardium, exerting direct paracrine and vasocrine effects on the heart and coronary vessels. Under physiological conditions, EAT supports myocardial energy metabolism and thermoregulation through fatty acid supply and
Elisabeth Heuboeck, Charnkamal Singh Bhogal, Markus Mandl   +2 more
wiley   +1 more source

The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial [PDF]

, 2016
Abhishek Mishra, Bruce W. Bode, Jean-Pierre Courrèges, Louis B. Chaykin, Lucine M. Lehmann, Richard W. Simpson, Sultan Linjawi, Yehuda Handelsman   +7 more
core   +1 more source

Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity: A Nationwide Analysis of 1.1 Million Patients. [PDF]

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated significant efficacy in obesity treatment beyond their original development for type-2 diabetes management.
Abdelmaksoud, Ahmed, Aiash, Hani, Attia, Abdallah, Elshazli, Rami, Levy, Shauna, Tatum, Danielle, Toraih, Eman   +6 more
core   +1 more source

Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists for incident dementia: A retrospective multicohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1443-1452, February 2026.
Abstract Objective This study provides real‐world evidence on the comparative effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) regarding the risk of incident dementia in adults with type 2 diabetes mellitus (T2DM).
Filippos Anagnostakis, Michail Kokkorakis, Shrihari Nagarajan, Georgia Anastasiou, Christos S. Mantzoros   +4 more
wiley   +1 more source